Who makes FP-02.2 Vaccine?

FP-02.2 Vaccine is developed by Altimmune, Inc..

Last reviewed 2026-05-14 · How we verify

FP-02.2 Vaccine

Altimmune, Inc. · Phase 1 active Biologic

At a glance

Generic name	FP-02.2 Vaccine
Sponsor	Altimmune, Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB) (PHASE2)
Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

FP-02.2 Vaccine CI brief — competitive landscape report
FP-02.2 Vaccine updates RSS · CI watch RSS
Altimmune, Inc. portfolio CI